Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Enters Strategic Collaboration to Advance AI Initiatives By: Investor Brand Network November 21, 2023 at 11:16 AM EST IGC Pharma (NYSE American: IGC) has announced its entry into a master cooperation agreement with the University of Los Andes for the development and adoption of generative AI solutions into the company’s drug identification, development and clinical trial processes. IGC Pharma will be focused on advancing various AI initiatives including streamlining clinical trial efficiency, enhancing early detection methods for Alzheimer’s disease, and improving drug interaction analysis. “We are very pleased to be partnering with the University of Los Andes to further our AI initiatives through the development and adoption of AI algorithms that have the potential to significantly enhance the treatment of Alzheimer’s disease and other chronic illnesses,” IGC Pharma CEO Ram Mukunda said of the collaboration. “We believe that generative AI solutions can have transformative applications for our company and the drug development industry overall, and we are committed to investing in and driving AI algorithm development and adoption. As we execute our strategic initiatives and position IGC Pharma at the forefront of AI adoption, we expect to gain a distinct competitive advantage as we streamline clinical trial efficiencies, enhance early detection of Alzheimer’s, improve methodologies for the analysis of drug interaction, and improve the treatment experience for patients, should our AI algorithms prove successful.” To view the full press release, visit https://ibn.fm/yve4N About IGC Pharma Inc. IGC Pharma is pioneering innovative solutions to combat Alzheimer’s disease and related challenges. The IGC Pharma portfolio comprises five assets all with a singular mission – to transform the landscape of Alzheimer’s treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques and neurofibrillary tangles. IGC-AD1 is currently in a phase 2b clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer’s. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles in a forward-thinking approach to Alzheimer’s therapy. In parallel, IGC Pharma is at the forefront of generative AI development, with projects including clinical trials, early detection of Alzheimer’s and drug interactions with cannabinoids. NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC About InvestorWire InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge. For more information, please visit https://www.InvestorWire.com Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer InvestorWireLos Angeles, CAwww.InvestorWire.com310.299.1717 OfficeEditor@InvestorWire.com InvestorWire is powered by IBN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Enters Strategic Collaboration to Advance AI Initiatives By: Investor Brand Network November 21, 2023 at 11:16 AM EST IGC Pharma (NYSE American: IGC) has announced its entry into a master cooperation agreement with the University of Los Andes for the development and adoption of generative AI solutions into the company’s drug identification, development and clinical trial processes. IGC Pharma will be focused on advancing various AI initiatives including streamlining clinical trial efficiency, enhancing early detection methods for Alzheimer’s disease, and improving drug interaction analysis. “We are very pleased to be partnering with the University of Los Andes to further our AI initiatives through the development and adoption of AI algorithms that have the potential to significantly enhance the treatment of Alzheimer’s disease and other chronic illnesses,” IGC Pharma CEO Ram Mukunda said of the collaboration. “We believe that generative AI solutions can have transformative applications for our company and the drug development industry overall, and we are committed to investing in and driving AI algorithm development and adoption. As we execute our strategic initiatives and position IGC Pharma at the forefront of AI adoption, we expect to gain a distinct competitive advantage as we streamline clinical trial efficiencies, enhance early detection of Alzheimer’s, improve methodologies for the analysis of drug interaction, and improve the treatment experience for patients, should our AI algorithms prove successful.” To view the full press release, visit https://ibn.fm/yve4N About IGC Pharma Inc. IGC Pharma is pioneering innovative solutions to combat Alzheimer’s disease and related challenges. The IGC Pharma portfolio comprises five assets all with a singular mission – to transform the landscape of Alzheimer’s treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques and neurofibrillary tangles. IGC-AD1 is currently in a phase 2b clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer’s. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles in a forward-thinking approach to Alzheimer’s therapy. In parallel, IGC Pharma is at the forefront of generative AI development, with projects including clinical trials, early detection of Alzheimer’s and drug interactions with cannabinoids. NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC About InvestorWire InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge. For more information, please visit https://www.InvestorWire.com Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer InvestorWireLos Angeles, CAwww.InvestorWire.com310.299.1717 OfficeEditor@InvestorWire.com InvestorWire is powered by IBN
IGC Pharma (NYSE American: IGC) has announced its entry into a master cooperation agreement with the University of Los Andes for the development and adoption of generative AI solutions into the company’s drug identification, development and clinical trial processes. IGC Pharma will be focused on advancing various AI initiatives including streamlining clinical trial efficiency, enhancing early detection methods for Alzheimer’s disease, and improving drug interaction analysis. “We are very pleased to be partnering with the University of Los Andes to further our AI initiatives through the development and adoption of AI algorithms that have the potential to significantly enhance the treatment of Alzheimer’s disease and other chronic illnesses,” IGC Pharma CEO Ram Mukunda said of the collaboration. “We believe that generative AI solutions can have transformative applications for our company and the drug development industry overall, and we are committed to investing in and driving AI algorithm development and adoption. As we execute our strategic initiatives and position IGC Pharma at the forefront of AI adoption, we expect to gain a distinct competitive advantage as we streamline clinical trial efficiencies, enhance early detection of Alzheimer’s, improve methodologies for the analysis of drug interaction, and improve the treatment experience for patients, should our AI algorithms prove successful.” To view the full press release, visit https://ibn.fm/yve4N About IGC Pharma Inc. IGC Pharma is pioneering innovative solutions to combat Alzheimer’s disease and related challenges. The IGC Pharma portfolio comprises five assets all with a singular mission – to transform the landscape of Alzheimer’s treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques and neurofibrillary tangles. IGC-AD1 is currently in a phase 2b clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer’s. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles in a forward-thinking approach to Alzheimer’s therapy. In parallel, IGC Pharma is at the forefront of generative AI development, with projects including clinical trials, early detection of Alzheimer’s and drug interactions with cannabinoids. NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC About InvestorWire InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge. For more information, please visit https://www.InvestorWire.com Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer InvestorWireLos Angeles, CAwww.InvestorWire.com310.299.1717 OfficeEditor@InvestorWire.com InvestorWire is powered by IBN
